The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Lupin is the 6th largest company in the Indian Pharmaceutical Market
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
PEL will explore the PLI scheme and apply if its beneficial.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Subscribe To Our Newsletter & Stay Updated
